101 related articles for article (PubMed ID: 38630383)
1. Retrospective Study of Claudin 18 Isoform 2 Prevalence and Prognostic Association in Gastric and Gastroesophageal Junction Adenocarcinoma.
Waters R; Sewastjanow-Silva M; Yamashita K; Abdelhakeem A; Iwata KK; Moran D; Elsouda D; Guerrero A; Pizzi M; Vicentini ER; Shanbhag N; Ta A; Chatterjee D; Ajani JA
JCO Precis Oncol; 2024 May; 8():e2300543. PubMed ID: 38781542
[TBL] [Abstract][Full Text] [Related]
2. New therapeutic target molecules for gastric and gastroesophageal junction cancer.
Kawakami H
Int J Clin Oncol; 2024 Apr; ():. PubMed ID: 38630383
[TBL] [Abstract][Full Text] [Related]
3. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy.
Cao W; Xing H; Li Y; Tian W; Song Y; Jiang Z; Yu J
Biomark Res; 2022 May; 10(1):38. PubMed ID: 35642043
[TBL] [Abstract][Full Text] [Related]
4. Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer.
Kubota Y; Shitara K
Ther Adv Med Oncol; 2024; 16():17588359231217967. PubMed ID: 38188462
[TBL] [Abstract][Full Text] [Related]
5. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.
Shah MA; Shitara K; Ajani JA; Bang YJ; Enzinger P; Ilson D; Lordick F; Van Cutsem E; Gallego Plazas J; Huang J; Shen L; Oh SC; Sunpaweravong P; Soo Hoo HF; Turk HM; Oh M; Park JW; Moran D; Bhattacharya P; Arozullah A; Xu RH
Nat Med; 2023 Aug; 29(8):2133-2141. PubMed ID: 37524953
[TBL] [Abstract][Full Text] [Related]
6. HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives.
Li W; Zhang X; Du Y; Zhang Y; Lu J; Hu W; Zhao J
Biomark Res; 2022 Sep; 10(1):71. PubMed ID: 36175985
[TBL] [Abstract][Full Text] [Related]
7. ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
Klempner SJ; Lee KW; Shitara K; Metges JP; Lonardi S; Ilson DH; Fazio N; Kim TY; Bai LY; Moran D; Yang J; Arozullah A; Park JW; Raizer JJ; Bang YJ; Shah MA
Clin Cancer Res; 2023 Oct; 29(19):3882-3891. PubMed ID: 37490286
[TBL] [Abstract][Full Text] [Related]
8. Multiomic spatial landscape of innate immune cells at human central nervous system borders.
Sankowski R; Süß P; Benkendorff A; Böttcher C; Fernandez-Zapata C; Chhatbar C; Cahueau J; Monaco G; Gasull AD; Khavaran A; Grauvogel J; Scheiwe C; Shah MJ; Heiland DH; Schnell O; Markfeld-Erol F; Kunze M; Zeiser R; Priller J; Prinz M
Nat Med; 2024 Jan; 30(1):186-198. PubMed ID: 38123840
[TBL] [Abstract][Full Text] [Related]
9. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
Shitara K; Lordick F; Bang YJ; Enzinger P; Ilson D; Shah MA; Van Cutsem E; Xu RH; Aprile G; Xu J; Chao J; Pazo-Cid R; Kang YK; Yang J; Moran D; Bhattacharya P; Arozullah A; Park JW; Oh M; Ajani JA
Lancet; 2023 May; 401(10389):1655-1668. PubMed ID: 37068504
[TBL] [Abstract][Full Text] [Related]
10. CEACAMS 1, 5, and 6 in disease and cancer: interactions with pathogens.
Thomas J; Klebanov A; John S; Miller LS; Vegesna A; Amdur RL; Bhowmick K; Mishra L
Genes Cancer; 2023; 14():12-29. PubMed ID: 36741860
[TBL] [Abstract][Full Text] [Related]
11. Futibatinib for
Goyal L; Meric-Bernstam F; Hollebecque A; Valle JW; Morizane C; Karasic TB; Abrams TA; Furuse J; Kelley RK; Cassier PA; Klümpen HJ; Chang HM; Chen LT; Tabernero J; Oh DY; Mahipal A; Moehler M; Mitchell EP; Komatsu Y; Masuda K; Ahn D; Epstein RS; Halim AB; Fu Y; Salimi T; Wacheck V; He Y; Liu M; Benhadji KA; Bridgewater JA;
N Engl J Med; 2023 Jan; 388(3):228-239. PubMed ID: 36652354
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer.
Kubota Y; Kawazoe A; Mishima S; Nakamura Y; Kotani D; Kuboki Y; Bando H; Kojima T; Doi T; Yoshino T; Kuwata T; Shitara K
ESMO Open; 2023 Feb; 8(1):100762. PubMed ID: 36610262
[TBL] [Abstract][Full Text] [Related]
13. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study.
Wainberg ZA; Enzinger PC; Kang YK; Qin S; Yamaguchi K; Kim IH; Saeed A; Oh SC; Li J; Turk HM; Teixeira A; Borg C; Hitre E; Udrea AA; Cardellino GG; Sanchez RG; Collins H; Mitra S; Yang Y; Catenacci DVT; Lee KW
Lancet Oncol; 2022 Nov; 23(11):1430-1440. PubMed ID: 36244398
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]